FTY720 does not abrogate acute graft-versus-host disease in the dog leukocyte antigen-nonidentical unrelated canine model

Transplantation

Volumn 76, Issue 8, 2003, Pages 1155-1158

  Lee, Richard S ^a,b   Kuhr, Christian S ^a,b   Sale, George E ^a,c   Zellmer, Eustacia ^a   Hogan, William J ^a   Storb, Rainer ^a,c   Little, Marie Térèse ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; LEUKOCYTE ANTIGEN; METHOTREXATE;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOG; DRUG EFFECT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE MIGRATION; LYMPHOID ORGAN; NONHUMAN; PRIORITY JOURNAL; RECURRENCE RISK; SURVIVAL; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ACUTE DISEASE; ANIMALS; DOGS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE COUNT; PROPYLENE GLYCOLS; RECURRENCE; SEVERITY OF ILLNESS INDEX; SPHINGOSINE;

EID: 0242363653     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000083891.14089.B8     Document Type: Article

References (11)

1. Storb R, Epstein RB, Graham TC, et al. Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplantation 1970; 9: 240.
2. Storb R, Deeg HJ, Raff R, et al. Prevention of graft-versus-host disease: Studies in a canine model [review]. Ann NY Acad Sci 1995; 770: 149.
3. Yu C, Seidel K, Nash RA, et al. Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. Blood 1998; 91: 2581.
4. Suzuki S, Enosawa S, Kakefuda T, et al. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation 1996; 61: 200.
5. Chiba K, Yanagawa Y, Masubuchi Y, et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats: I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 1998; 160: 5037.
6. Xun C-Q, Little M-T, Zellmer E, et al. What role for FTY720, a novel immunosuppressive agent, in canine nonmyeloablative hematopoietic stem cell transplantation? Transplantation 2002; 73: 310.
7. Sale GE, Shulman HM, Hackman RC. Pathology of hematopoietic cell transplantation. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic cell transplantation [ed 2]. Boston: Blackwell Science 1999, p 248.
8. Yu C, Linsley P, Seidel K, et al. Cytotoxic T lymphocyte antigen 4-immunoglobulin fusion protein combined with methotrexate/cyclosporine as graft-versus-host disease prevention in a canine dog leukocyte antigen-nonidentical marrow transplant model. Transplantation 2000; 69: 450.
9. Storb R, Kolb HJ, Graham TC, et al. Treatment of established graft-versus-host disease in dogs by antithymocyte serum or prednisone. Blood 1973; 42: 601.
10. Ochs HD, Storb R, Thomas ED, et al. Immunologic reactivity in canine marrow graft recipients. J Immunol 1974; 113: 1039.
11. Storb R, Kolb HJ, Deeg HJ, et al. Prevention of graft-versus-host disease by immunosuppressive agents after transplantation of DLA-nonidentical canine marrow. Bone Marrow Transplant 1986; 1: 167.